CurrentCignaPolicy N/A

Oncology (Oral - Menin Inhibitor) - Komzifti Prior Authorization Policy

Defines prior authorization coverage criteria for Komzifti (ziftomenib capsules) under Cigna benefit plans for the FDA-approved indication and states noncoverage for other uses. Approvals are for a duration of one year when criteria are met.

Policy Summary

PayerCigna

PolicyOncology (Oral - Menin Inhibitor) - Komzifti Prior Authorization Policy

Policy CodePolicy N/A

Change TypeOverview updated (NCCN v3.2026)

Effective Date

Next Review Date

Key ActionPrior Authorization is required; approvals provided for 1 year when coverage criteria are met.

SourceLink

POLICY UPDATE CHANGES

Overview section updated to include updated guideline information (NCCN v3.2026).

New Policy created with review date 11/13/2025.

1Covered Indications

1 yrApproval Duration

≥18Age Requirement

Coverage Summary

FDA-Approved Indication (Acute Myeloid Leukemia)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage stance: covered_with_criteria — Komzifti is covered when the FDA‑approved criteria are met. Scope: Defines prior authorization coverage criteria for Komzifti (ziftomenib capsules) under Cigna benefit plans for the FDA‑approved indication and states noncoverage for other uses. Typical approval duration: 1 year when criteria are met. Age requirement: Age ≥18. Komzifti indicated for relapsed/refractory AML with susceptible NPM1 mutation; approvals for 1 year when criteria met; noncovered for other uses.

Provider Actions & Authorization Requirements

Prior Authorization

Prior authorization required

Prior Authorization is recommended/required for prescription benefit coverage of Komzifti. Approvals are provided for a duration of 1 year when the coverage criteria are met.

Documentation Required

Documentation of mutation status

Documentation that the disease is positive for a susceptible NPM1 mutation must be provided to meet coverage criteria (presence of a susceptible NPM1 mutation per FDA labeling/prescribing information).

Documentation Required

Age and disease status documentation

Documentation that the patient is ≥ 18 years of age and has relapsed or refractory disease must be provided to meet coverage criteria.

Clinical Evidence & Guidelines

Prescribing information: Komzifti capsules prescribing information, Kura Oncology, November 2025.

Guideline: NCCN Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology (version 3.2026 November 24, 2025) — NCCN lists Komzifti as a category 2A option for relapsed/refractory AML with NPM1 mutation.

Background

Komzifti (ziftomenib) is a menin inhibitor indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation in adult patients who have no satisfactory alternative treatment options. The FDA indication and NCCN placement support its use in this setting; NCCN lists Komzifti as a category 2A option for relapsed/refractory AML with NPM1 mutation.

Quick Facts

Covered Indications1 (relapsed/refractory AML with susceptible NPM1 mutation)

Typical Approval Duration1 year

Last Review2025-11-13

Definitions:

Susceptible NPM1 mutation — Presence of an NPM1 mutation considered susceptible per FDA labeling/prescribing information (documentation required).